JP2020079729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020079729A5 JP2020079729A5 JP2018212341A JP2018212341A JP2020079729A5 JP 2020079729 A5 JP2020079729 A5 JP 2020079729A5 JP 2018212341 A JP2018212341 A JP 2018212341A JP 2018212341 A JP2018212341 A JP 2018212341A JP 2020079729 A5 JP2020079729 A5 JP 2020079729A5
- Authority
- JP
- Japan
- Prior art keywords
- urinary tumor
- neuroblastoma
- group
- subject
- tumor marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002485 urinary effect Effects 0.000 claims 26
- 206010029260 Neuroblastoma Diseases 0.000 claims 19
- 239000000439 tumor marker Substances 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 claims 8
- VURKRJGMSKJIQX-UHFFFAOYSA-N xanthopterin Chemical compound N1C(=O)C=NC2=C1C(=O)N=C(N)N2 VURKRJGMSKJIQX-UHFFFAOYSA-N 0.000 claims 8
- 229960000890 hydrocortisone Drugs 0.000 claims 6
- -1 vanyllactate Chemical compound 0.000 claims 6
- RILPIWOPNGRASR-RFZPGFLSSA-N (2R,3R)-2-hydroxy-3-methylpentanoic acid Chemical compound CC[C@@H](C)[C@@H](O)C(O)=O RILPIWOPNGRASR-RFZPGFLSSA-N 0.000 claims 5
- ORZHQEJEAKXCJA-UHFFFAOYSA-N 3-methoxytyramine sulfate Chemical compound COc1cc(CC[NH3+])ccc1OS([O-])(=O)=O ORZHQEJEAKXCJA-UHFFFAOYSA-N 0.000 claims 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-M 3,4-Dihydroxyphenylacetate Chemical compound OC1=CC=C(CC([O-])=O)C=C1O CFFZDZCDUFSOFZ-UHFFFAOYSA-M 0.000 claims 4
- ZQTJTTSZJNFQGJ-UHFFFAOYSA-N 3,4-Dihydroxyphenylacetate sulfate Chemical compound OC(=O)CC1=CC=C(OS(O)(=O)=O)C(O)=C1 ZQTJTTSZJNFQGJ-UHFFFAOYSA-N 0.000 claims 4
- RHVCAYPGAKFGLL-UHFFFAOYSA-N 3,4-dihydroxyphenyl acetate Natural products CC(=O)OC1=CC=C(O)C(O)=C1 RHVCAYPGAKFGLL-UHFFFAOYSA-N 0.000 claims 4
- JVGVDSSUAVXRDY-UHFFFAOYSA-M 3-(4-hydroxyphenyl)lactate Chemical compound [O-]C(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-M 0.000 claims 4
- FBWPWWWZWKPJFL-UHFFFAOYSA-N 3-Methoxy-4-hydroxyphenylethyleneglycol Chemical compound COC1=CC(C(O)CO)=CC=C1O FBWPWWWZWKPJFL-UHFFFAOYSA-N 0.000 claims 4
- PFDUUKDQEHURQC-UHFFFAOYSA-N 3-Methoxytyrosine Chemical compound COC1=CC(CC(N)C(O)=O)=CC=C1O PFDUUKDQEHURQC-UHFFFAOYSA-N 0.000 claims 4
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 claims 4
- CGQCWMIAEPEHNQ-UHFFFAOYSA-N Vanillylmandelic acid Chemical compound COC1=CC(C(O)C(O)=O)=CC=C1O CGQCWMIAEPEHNQ-UHFFFAOYSA-N 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 4
- 210000002700 urine Anatomy 0.000 claims 3
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 claims 2
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 claims 2
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000000491 multivariate analysis Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018212341A JP7226732B2 (ja) | 2018-11-12 | 2018-11-12 | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 |
| EP19207022.5A EP3650862A3 (en) | 2018-11-12 | 2019-11-05 | Method, kit, and apparatus for cancer detection using urinary tumor markers |
| US16/675,109 US11415583B2 (en) | 2018-11-12 | 2019-11-05 | Method, kit, and apparatus for cancer detection using urinary tumor markers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018212341A JP7226732B2 (ja) | 2018-11-12 | 2018-11-12 | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020079729A JP2020079729A (ja) | 2020-05-28 |
| JP2020079729A5 true JP2020079729A5 (enExample) | 2021-09-16 |
| JP7226732B2 JP7226732B2 (ja) | 2023-02-21 |
Family
ID=68468565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018212341A Active JP7226732B2 (ja) | 2018-11-12 | 2018-11-12 | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US11415583B2 (enExample) |
| EP (1) | EP3650862A3 (enExample) |
| JP (1) | JP7226732B2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7550419B2 (ja) * | 2020-02-17 | 2024-09-13 | 国立大学法人東海国立大学機構 | 新規検査開発サーバ及び新規検査開発方法 |
| CN116034273A (zh) * | 2020-09-09 | 2023-04-28 | 株式会社日立高新技术 | 利用代谢物面板的癌症检查法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05113438A (ja) | 1991-03-25 | 1993-05-07 | Tosoh Corp | カテコールアミン類とカテコールアミン代謝産物の同時分析法及びそのための分析装置 |
| JP2012506380A (ja) | 2008-10-21 | 2012-03-15 | エンゾン ファーマシューティカルズ，インコーポレーテッド | ７−エチル−１０−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療 |
| WO2015112429A1 (en) * | 2014-01-23 | 2015-07-30 | Newomics Inc | Methods and systems for diagnosing diseases |
| WO2017213246A1 (ja) * | 2016-06-10 | 2017-12-14 | 株式会社日立製作所 | 尿中代謝物による疾病診断法 |
| JP6760597B2 (ja) | 2016-09-29 | 2020-09-23 | 国立研究開発法人産業技術総合研究所 | 電極スラリー及びそれを用いた電極の製造方法 |
| JP7016079B2 (ja) * | 2018-03-23 | 2022-02-04 | 国立大学法人東海国立大学機構 | 小児がん検査用尿中代謝物マーカー |
-
2018
- 2018-11-12 JP JP2018212341A patent/JP7226732B2/ja active Active
-
2019
- 2019-11-05 US US16/675,109 patent/US11415583B2/en active Active
- 2019-11-05 EP EP19207022.5A patent/EP3650862A3/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verplanken et al. | Rapid evaporative ionization mass spectrometry for high-throughput screening in food analysis: The case of boar taint | |
| Björkhem et al. | Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease | |
| JP2018509934A5 (enExample) | ||
| JP7288283B2 (ja) | 小児がん検査用尿中代謝物マーカー | |
| US10194833B2 (en) | Method and apparatus for non-invasive detection of conditions such as lung cancer | |
| JP6692422B2 (ja) | 尿中代謝物による疾病診断法 | |
| JP2020526747A5 (enExample) | ||
| US20180275131A1 (en) | Cancer development risk assessment device, program, and method for testing cancer development risk | |
| JP2018529931A5 (enExample) | ||
| JP2019505005A5 (enExample) | ||
| JP6857597B2 (ja) | 尿中代謝物におけるバイオマーカー探索法 | |
| JP2020079729A5 (enExample) | ||
| CN106370744A (zh) | 8‑羟基脱氧鸟苷作为尿液标志物的应用 | |
| Dervilly-Pinel et al. | When LC-HRMS metabolomics gets ISO17025 accredited and ready for official controls–application to the screening of forbidden compounds in livestock | |
| JP7226732B2 (ja) | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 | |
| JP2020034538A (ja) | 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー | |
| JP2020064055A (ja) | 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー | |
| Robinson et al. | Elevated and similar urinary testosterone/epitestosterone ratio in all samples of a competition testing: suspicion of a manipulation | |
| JP2010266386A (ja) | 患者由来の代謝物を使用したがんの検査方法 | |
| CN101523219A (zh) | 与磷脂沉积症有关的线粒体毒性的生物标记 | |
| CN113252818A (zh) | 一种采用基准样品对同系列化合物进行定量和评价的方法 | |
| Lubimova et al. | Serum immunoglobulin free light chains in patients with monoclonal gammapathies | |
| US20180185838A1 (en) | A biochemical analytical technique | |
| Cheng et al. | Plasma proteomic profiling of baseline biomarkers associated with high resolution CT (HRCT) in the TESRA cohort | |
| Piestansky | Simple UHPLC-MS method in targeted metabolomic profiling of Crohn's disease patients |